Literature DB >> 9815979

The emerging role of paclitaxel in breast cancer therapy.

A D Seidman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 9815979

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity.

Authors:  Hyeong Sim Choi; Sung-Gook Cho; Min Kyoung Kim; Hee Jae Lee; Seung Hee Moon; Hee Jae Jang; Seong-Gyu Ko
Journal:  Mol Cell Biochem       Date:  2016-11-16       Impact factor: 3.396

2.  Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

Authors:  D Papamichael; C J Gallagher; R T Oliver; P W Johnson; J Waxman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').

Authors:  G Blackledge
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

4.  Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.

Authors:  P Pedrazzoli; C Perotti; G A Da Prada; F Bertolini; N Gibelli; L Torretta; M Battaglia; L Pavesi; P Preti; L Salvaneschi; G Robustelli della Cuna
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.

Authors:  Diane Pannier; Antoine Adenis; Emilie Bogart; Eric Dansin; Stéphanie Clisant-Delaine; Emilie Decoupigny; Anne Lesoin; Eric Amela; Sandrine Ducornet; Jean-Pierre Meurant; Marie-Cécile Le Deley; Nicolas Penel
Journal:  BMC Cancer       Date:  2018-07-31       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.